Abstract: Disclosed herein is a post repair kit comprising a stake defined by a body, proximal end, and a tapered anchor end. The post repair kit comprises a hammer mechanism comprising a power portion and a reciprocating ram structure, the power portion forcibly driving the reciprocating ram structure in a reciprocating motion. The reciprocating ram structure comprises a rod structure having a proximal end coupled with the power portion. The reciprocating ram structure further comprises an offset member connected to a distal end of the rod structure. The offset member has a first hole and a second hole. The distal end of the rod structure is connected to the first hole, wherein the offset member and the rod structure are connected perpendicular to each other. The reciprocating ram structure further comprises an interchangeable adaptor end tool detachably connected to the offset member using a fastening mechanism at the second hole.

Abstract: The present invention relates to novel cGAS inhibitor compounds, having a formula of: to pharmaceutical compositions comprising the compounds, and to methods of using the compounds and compositions to treat certain pathological conditions such as immune-mediated diseases.

Abstract: An oral care composition with gum health compound, amino acid, and/or mucoadhesive compound. An oral care composition with gum health compound, a pentapeptide, such as palmitoyl KTTKS, and/or a mucoadhesive compound. Methods of preventing gingival recession, stopping gingival recession, reversing gingival recession, decrease gum recession, increase gingival barrier protection, promoting collagen synthesis, promoting extracellular matrix synthesis, increasing gum resilience, increasing epidermal thickness and/or promoting fibrillin synthesis, in an oral cavity of an animal by contacting the oral care compositions with at least one surface of the oral cavity.

Abstract: An oral care composition with gum health compound, amino acid, and/or mucoadhesive compound. An oral care composition with gum health compound, a pentapeptide, such as palmitoyl KTTKS, and/or a mucoadhesive compound. Methods of preventing gingival recession, stopping gingival recession, reversing gingival recession, decrease gum recession, increase gingival barrier protection, promoting collagen synthesis, promoting extracellular matrix synthesis, increasing gum resilience, increasing epidermal thickness and/or promoting fibrillin synthesis, in an oral cavity of an animal by contacting the oral care compositions with at least one surface of the oral cavity.

Abstract: A reclosable beverage can end (10) has a circumferential curl (14) centered about a center longitudinal axis (50). A circumferential wall (15) extends downwardly from the curl (14) and inwardly towards the longitudinal axis (50). A center panel (12) is produced from a metallic material and centered about the longitudinal axis (50). The center panel (12) has a public side (34) and an opposing product side (35). A tab (26) is mounted to the public side (34) of the center panel (12). A pour opening (20) is formed by an aperture in the center panel (12) and sealed by the tab (26). The pour opening (20) is at least partially defined by a pour opening curl (22) of the metallic material of the center panel (12).

Abstract: A method and system for scheduling tasks using a counter constraint. A method may include identifying multiple tasks to be performed, receiving dependency data indicating that scheduling of at least one task is dependent on whether a counter satisfies a threshold in relation to an additional condition, and upon determining, during scheduling, that the counter satisfies the threshold in relation to the additional condition, triggering a scheduling action with respect to at least one task.

Abstract: Human skin tissue sample methods and models for identifying and screening test agents as effective for providing skin tone benefits, methods for validating hypotheses for mechanisms driving skin pigmentation as well as methods for driving skin pigment levels in ex-vivo skin tissue. The method includes contacting a cultured human skin tissue sample with a test agent, generating a transcriptional profile from the sample, and comparing the results to a control to determine if the test agent is effective for providing a skin tone benefit.

Abstract: Methods and systems for constructing a gene expression signature representative of a number of biological conditions, systems and methods for determining functional relationships between a skin-active agent and skin conditions of interest, and methods and systems for identifying skin-active agents with broad spectrum activity are provided.

Abstract: Methods and systems for constructing a gene expression signature representative of a number of biological conditions, systems and methods for determining functional relationships between a skin-active agent and skin conditions of interest, and methods and systems for identifying skin-active agents with broad spectrum activity are provided.

Abstract: An array of methods for assessing vaginal atrophy are disclosed. The methods may be used alone or in combination with a treatment or as part of a kit.

Abstract: Provided are methods and systems for determining functional relationships between ex vivo skin models and an inflammatory skin condition. Also provided are methods and systems for identifying modulators of inflammation of skin, as well as the use of modulators identified by such methods or systems for the preparation of cosmetic compositions, personal care products, or both.

Abstract: An array of methods for assessing vaginal atrophy are disclosed. The methods may be used alone or in combination with a treatment or as part of a kit.

Abstract: A kit for assessing efficacy of a vaginal atrophy treatment regimen is disclosed. The kit includes a pretreatment assessment method for vaginal atrophy comprising and a topical treatment for application to the labia majora, labia minora, introitus, vagina, or combinations thereof.

Abstract: A screening method for identifying an agent as effective for providing an anti-aging skin benefit is provided. The screening method includes culturing first and second human skin samples from about 3 days to about 19 days, wherein the first and second human skin samples are derived from a human skin surgical waste tissue. The first human skin sample is contacted with at least one test agent. The second human skin sample is contacted with a positive control. Transcriptional profiles are generated from the first and second human skin samples, and the at least one test agent is identified as effective for providing an anti-aging skin benefit when the transcriptional profiles of at least two genes show a similar directional change in comparison to one or more untreated control tissue samples.

Abstract: Among other things, one or more techniques and/or systems are provided for sustained data protection. In particular, a data protector may define a set of access levels associated with content within data using a set of access policies (e.g., a partial access level to inventory data for an inventory server, a full access level to inventory data and billing data for a shopping website server, etc.). The data protector may secure (e.g., encrypt) the data to create protected data, so that clients may be unable to access content of the protected data without obtaining access through the data protector. In this way, the data protector may selectively provide clients with access to content within the protected data according to respective access levels for the different clients (e.g., access to inventory data, but not billing data, may be provided to the inventory server by the data protector).

Abstract: An array of methods for assessing vaginal atrophy are disclosed. The methods may be used alone or in combination with a treatment or as part of a kit.

Abstract: An array of methods for assessing vaginal atrophy are disclosed. The methods may be used alone or in combination with a treatment or as part of a kit.

Abstract: Human skin tissue sample methods and models for identifying and screening test agents as effective for providing skin tone benefits, methods for validating hypotheses for mechanisms driving skin pigmentation as well as methods for driving skin pigment levels in ex-vivo skin tissue. The method includes contacting a cultured human skin tissue sample with a test agent, generating a transcriptional profile from the sample, and comparing the results to a control to determine if the test agent is effective for providing a skin tone benefit.

Abstract: Human skin tissue sample methods and models for validating hypotheses for mechanisms driving skin pigmentation as well as methods for driving skin pigment levels in ex-vivo skin tissue. The method includes providing a first cultured human skin tissue sample and testing the effectiveness of the test agent for driving skin pigmentation, and comparing the transcriptional profile generated from the treated human skin tissue sample to the transcriptional profile of a control to validate the hypothesis that the test agent drives skin pigmentation.

Abstract: A screening method for identifying an agent as effective for providing an anti-aging skin benefit is provided. The screening method includes culturing first and second human skin samples from about 3 days to about 19 days, wherein the first and second human skin samples are derived from a human skin surgical waste tissue. The first human skin sample is contacted with at least one test agent. The second human skin sample is contacted with a positive control. Transcriptional profiles are generated from the first and second human skin samples, and the at least one test agent is identified as effective for providing an anti-aging skin benefit when the transcriptional profiles of at least two genes show a similar directional change in comparison to one or more untreated control tissue samples.